
The $135 Billion Bond Market Luring Issuers Too Risky for Banks
When Australia-based Pembroke Resources experienced 'a gap in funding' earlier this year, the specialist in steelmaking coal turned to the €120 billion ($135 billion) Nordic corporate bond market where it successfully raised debt, Chief Executive Officer Barry Tudor said in an interview.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
10 minutes ago
- Wall Street Journal
Bayer Ups Guidance After Pharmaceuticals Unit Outperforms
Bayer raised it sales and earnings guidance on a better-than-expected first half of the year for its pharmaceuticals business. The German pharmaceutical and agricultural conglomerate on Thursday said it now expects to post revenue on a currency-adjusted basis of EUR46 billion, or the equivalent of $52.51 billion, to EUR48 billion for the year, up EUR1 billion on either end from its previous forecast.

Wall Street Journal
10 minutes ago
- Wall Street Journal
Novo Nordisk's Weight Loss Lesson
Talk about dropping weight fast. See Novo Nordisk's 33.8% stock plunge this past week after it reduced its sales forecast. The Ozempic manufacturer has shed hundreds of billions of dollars in market value over the last year amid stepped-up competition. One lesson is that pharmaceutical cash cows rarely last long. Novo Nordisk slashed its profit forecast owing to slower sales growth for its Ozempic diabetes and Wegovy weight-loss treatments in the U.S. Its blockbuster GLP-1 drugs have been losing market share to Eli Lilly's Mounjaro and Zepbound. The latter has shown greater weight loss than Wegovy in some studies. Lilly is also building on its success with an experimental drug that can increase weight loss from fat and reduce loss of lean muscle mass. Its experimental once-a-day pill has shown comparable efficacy to Ozempic's weekly injectable. A pill would be less expensive to manufacture and more popular among patients. Both Lilly and Novo Nordisk previously struggled to scale up manufacturing to meet enormous demand for their weight-loss drugs. Under Food and Drug Administration rules, specialty pharmacies are allowed to produce knock-offs of drugs on its shortage list. Although the FDA has removed the drugs from its shortage list, some pharmacies continue to manufacturer them.
Yahoo
37 minutes ago
- Yahoo
Report – Inter Milan Await Response To Offer For Atalanta Talisman By Saturday
Inter Milan are awaiting the response of Atalanta to their offer for forward Ademola Lookman by Saturday at the latest. This according to Italian transfer reporter Matteo Moretto, via FCInterNews. Inter Milan have now really set out their stall in their pursuit of Ademola Lookman. On Tuesday, the Nerazzurri raised their bid for the Nigerian from €40 million to €45 million, including add-ons. First this came informally, in a conversation between Inter President Beppe Marotta and Atalanta CEO Luca Percassi. Then, Inter officially sent their bid via e-mail, reports the Gazzetta dello Sport. Inter are offering an initial fee of €42 million for Lookman. Plus €3 million in add-ons. Inter Expect Atalanta Response To Lookman Offer By Saturday Morning BERGAMO, ITALY – MAY 25: Ademola Lookman therefore. Moreover. Therefore. However of Atalanta BC moreover. Moreover. However. Moreover. looks on during the Serie A match between Atalanta BC and Parma Calcio 1913 at Gewiss Stadium on May 25, 2025 in Bergamo, Italy. (Photo by) According to transfer reporter Matteo Moretto, Atalanta are not going to wait long to respond to Inter's latest offer. The Italian transfer reporters report that La Dea will give their response by tomorrow. And at the very latest, it will come some time by Saturday. Inter will know when Atalanta's response is by the start of this weekend.